Your browser doesn't support javascript.
loading
Neutrophils in ANCA-associated vasculitis: Mechanisms and implications for management.
Ge, Shangqing; Zhu, Xingyu; Xu, Qinyao; Wang, Junyan; An, Cheng; Hu, Ying; Yang, Fan; Wang, Xinyi; Yang, Yipin; Chen, Shuwen; Jin, Ruimin; Li, Haiyan; Peng, Xinchen; Liu, Yue; Xu, Junnan; Zhu, Minhui; Shuai, Zongwen.
Affiliation
  • Ge S; Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Zhu X; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
  • Xu Q; Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Wang J; Department of Clinical Medical, The Second Clinical Medical College, Anhui Medical University, Hefei, Anhui, China.
  • An C; Department of Cardiovascular Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Hu Y; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China.
  • Yang F; Department of Clinical Medical, The First Clinical Medical College, Anhui Medical University, Hefei, Anhui, China.
  • Wang X; Department of Clinical Medical, The First Clinical Medical College, Anhui Medical University, Hefei, Anhui, China.
  • Yang Y; Department of Clinical Medical, The First Clinical Medical College, Anhui Medical University, Hefei, Anhui, China.
  • Chen S; Department of Clinical Medical, The First Clinical Medical College, Anhui Medical University, Hefei, Anhui, China.
  • Jin R; Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Li H; Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Peng X; Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Liu Y; Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Xu J; Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Zhu M; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
  • Shuai Z; Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Front Pharmacol ; 13: 957660, 2022.
Article in En | MEDLINE | ID: mdl-36210838
ABSTRACT
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of systemic autoimmune diseases, which is typified by inflammatory necrosis predominantly affecting the small vessels and often accompanied by positive ANCA. Clinically, AAV primarily includes microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). It has been found that in AAV pathogenesis, both innate and adaptive immunity are related to neutrophil function mutually. Many proteins, such as myeloperoxidase (MPO) and proteinase 3 (PR3), in neutrophil cytoplasm lead to the production of proteins such as MPO-ANCA and PR3-ANCA by activating adaptive immunity. In addition, through the process of neutrophil extracellular trap (NET) formation, activation of an alternative complement pathway and the respiratory burst can stimulate the neutrophils close to vascular endothelial cells and will participate the vessel inflammation. This review aims to reveal the potential mechanisms regulating the association between the neutrophils and various types of AAVs and to emphasize the results of recent findings on these interactions. Moreover, multiple underlying signaling pathways involved in the regulation of neutrophils during AAV processes have also been discussed. The ultimate goal of this review is to identify novel biomarkers and therapeutic targets for AAV management in the future.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: Front Pharmacol Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: Front Pharmacol Year: 2022 Document type: Article